Perioperative Management of Apixaban

Preoperative Discontinuation

The American College of Chest Physicians recommends holding apixaban for 1 day (24 hours) before low-to-moderate bleeding risk procedures and 2 days (48 hours) before high bleeding risk procedures in patients with normal renal function 1
For low-to-moderate bleeding risk procedures, stopping apixaban 1 day (24 hours) before surgery achieves minimal residual anticoagulant effect, corresponding to approximately 2-3 half-lives 1, 2
Examples of low-to-moderate bleeding risk procedures include arthroscopy, laparoscopic cholecystectomy, abdominal hernia repair, colonoscopy with biopsy, and coronary angiography 2
For high bleeding risk procedures, stopping apixaban 2 days (48 hours) before surgery achieves minimal residual anticoagulant effect, corresponding to approximately 4-5 half-lives 1, 2
Examples of high bleeding risk procedures include cardiac surgery, intracranial/spinal surgery, major abdominal surgery, and surgery in highly vascular organs 2, 3

For neuraxial procedures, apixaban should be stopped 3 days (72 hours) before spinal or epidural anesthesia, even with normal renal function, due to the catastrophic risk of epidural hematoma 2, 3

Renal function assessment is mandatory before determining the discontinuation timeline, as apixaban has 25-27% renal clearance 2, 4
For patients with moderate renal impairment (CrCl 30-50 mL/min), consider longer interruption periods, though specific guidance is limited 3, 4

The American College of Chest Physicians recommends against using bridging anticoagulation during the interruption period, as it increases hemorrhagic risk without reducing thrombotic events 1, 2, 3
Bridging anticoagulation should be reserved for very high thrombotic risk patients after multidisciplinary discussion 3

Apixaban can be resumed at least 24 hours after low bleeding risk surgery once adequate hemostasis is established, with full dose (5 mg twice daily) resumed 24 hours postoperatively 1, 3, 4
For high bleeding risk procedures, apixaban can be resumed 48-72 hours postoperatively, with consideration of reduced dose (2.5 mg twice daily) for the first 2-3 days in high thrombotic risk patients undergoing major surgery 1, 3, 4

Do not use INR or aPTT to guide timing, as apixaban's effect on these tests is inconsistent and unreliable for surgical clearance 2
Do not routinely measure apixaban concentrations when recommended interruption periods are followed 3
Do not resume therapeutic-dose apixaban in the presence of an epidural catheter 3

For patients with impaired renal function undergoing major surgery, the American College of Cardiology recommends restarting apixaban 48-72 hours postoperatively once adequate hemostasis is established, and consider using a reduced dose (2.5 mg twice daily) for the first 2-3 days before advancing to full therapeutic dosing 5, 6
The Association of Anaesthetists guideline recommends resuming apixaban 48-72 hours after high bleeding risk surgery, with consideration of prophylactic LMWH bridging if bleeding concerns persist 6

For high thrombotic risk patients undergoing major surgery, initiate with reduced dose apixaban 2.5 mg twice daily for the first 2-3 days, then advance to full therapeutic dose (5 mg twice daily, or 2.5 mg twice daily if dose reduction criteria are met) 5, 7

For patients with moderate renal impairment (CrCl 30-50 mL/min), consider longer interruption periods and delayed resumption of apixaban 5, 6
The 2025 Association of Anaesthetists guideline recommends 3 days of preoperative cessation for patients with CrCl <30 mL/min, suggesting these patients may also require more cautious postoperative resumption 6

For patients with recent VTE (within 3 months) or atrial fibrillation with recent stroke/TIA (within 3 months) or CHA₂DS₂-VASc score with multiple risk factors, the reduced-dose stepwise approach (2.5 mg twice daily initially) is particularly important to balance risks 5, 6